ADPKD
ADPKD
Part of NephTimes
Advertisement
Charlotte RobinsonADPKD | April 12, 2024
A study evaluated the Mayo imaging classification's ability to predict kidney outcomes in ADPKD.
Read More
Victoria SochaADPKD | April 8, 2024
Researchers compared factors associated with intracranial aneurysm in patients with ADPKD.
Charlotte RobinsonADPKD | April 3, 2024
The FDA granted orphan drug designation to AP303 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Charlotte RobinsonADPKD | April 2, 2024
Nephrologist Ronald Perrone, MD, has joined the clinical advisory board of XORTX Therapeutics, Inc.
Charlotte RobinsonADPKD | April 1, 2024
The FDA approved a clinical trial of VX-407 to treat autosomal dominant polycystic kidney disease.
Victoria SochaADPKD | March 11, 2024
Researchers examined the association between good nutritional status and preservation of kidney function in ADPKD.
Victoria SochaADPKD | February 8, 2024
Unilateral nephrectomy resulted in a decrease of 46.4% in urinary EGF excretion, and a decrease of 35.2% in eGFR.
Victoria SochaADPKD | February 5, 2024
Patients with autosomal dominant polycystic kidney disease commonly progress to ESRD in the fifth decade of life.
Victoria SochaADPKD | February 5, 2024
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the accumulation of fluid-filled cysts in the kidney
Victoria SochaADPKD | February 5, 2024
Results of a study evaluating the prevalence of common comorbid conditions in patients with ADPKD.
Victoria SochaADPKD | February 5, 2024
Clinical development models for polycystic kidney disease remain challenging.
Victoria SochaASN Kidney Week 2023 | February 5, 2024
Tolvaptan showed real-world effectiveness in slowing decline in eGFR when compared with matched historical controls.
Victoria SochaADPKD | February 5, 2024
Patients with autosomal dominant polycystic kidney disease commonly develop end-stage kidney disease.
Victoria SochaADPKD | February 5, 2024
First, an automated kidney volume segmentation model is used to accurately calculate htTKV.
Victoria SochaADPKD | February 5, 2024
A literature review of possible nonpharmacological therapeutic strategies to slow enlargement of cysts in ADPKD.
Victoria SochaADPKD | February 5, 2024
The CKiD equation was associated with the highest prevalence of hyperfiltration (35%).
Victoria SochaADPKD | February 5, 2024
Disease acceptance among patients with autosomal dominant polycystic kidney disease.
Victoria SochaNKF Spring Clinical Meetings 2023 | February 5, 2024
Health-related quality of life (HRQoL) is adversely affected in patients with autosomal dominant polycystic kidney ...
Victoria SochaNephrology Times | February 5, 2024
The most common renal replacement therapies for patients with end-stage renal disease (ESRD) are peritoneal dialysis and ...
Victoria SochaNephrology Times | February 5, 2024
The most common inherited kidney disease is autosomal dominant polycystic kidney disease(ADPKD). According to Shunlai ...
Advertisement
Advertisement
Advertisement
Latest News

April 19, 2024